Cortexyme Stock News

Cortexyme Inc. (NASDAQ:CRTX) has seen 1.4 million shares traded in the last trading session. The company, currently valued at $368.55M, closed the last trade at $12.43 per share which meant it gained $0.4 on the day or 3.33% during that session. The CRTX stock price is -881.34% off its 52-week high price of $121.98 and Cortexyme Inc. (CRTX) Slumps 3.33%, A Gain For Bears Read More »

This move is a reversal from the hour prior, which saw price move down. The post Cortexyme Inc (CRTX): Price Now Near $12.69; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .

Cortexyme Inc. (NASDAQ:CRTX) price on Thursday, November 18, fall -7.86% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $12.90. A look at the stock’s price movement, the close in the last trading session was $14.00, moving within a range at $12.84 and $14.13. The beta value (5-Year … Cortexyme Inc. (NASDAQ:CRTX) Stock Could Be Worth Considering Read More »

Cortexyme Inc. (NASDAQ:CRTX)s traded shares stood at 1.3 million during the last session. At the close of trading, the stocks price was $14.00, to imply a decrease of -4.70% or -$0.69 in intraday trading. The CRTX shares 52-week high remains $121.98, putting it -771.29% down since that peak but still an impressive 11.36% since price Cortexyme Inc. (NASDAQ: CRTX): Can A Stock Be -49.60% Lower Year-To-Date And Still Be A Loser? Read More »

Cortexyme: A Challenging Path Forward

Cortexyme Inc (NASDAQ: CRTX) has presented additional data from its Phase 2/3 GAIN Trial at the Clinical Trials on Alzheimer's Disease Conference.  The 643-participant 48-week GAIN Trial failed t

Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.

Someone with a lot of money to spend (and possibly insider knowledge) has taken a bullish stance on Cortexyme (NASDAQ:CRTX). And retail traders should know.

The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.

Another new drug candidate for the treatment of Alzheimer's disease failed miserably in a clinical trial.

Today, investors in CRTX stock lament a rather poor announcement from the company that a key clinical trial missed its primary endpoint. The post CRTX Stock: What to Know as Cortexyme Plummets 75% app

Cortexyme Inc (NASDAQ: CRTX) shares are trading lower after the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints. Cortexyme says they will present the additional top-line results f

An Alzheimer's disease trial failure was much worse than the company's relatively upbeat look forward suggests.

Shares of Cortexyme Inc. CRTX, -73.76% tumbled 72.7% in trading on Wednesday, the day after the company said a late-stage clinical trial evaluating its experimental Alzheimer's disease treatment faile

Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc (NASDAQ: CRTX) reported Phase 2/3 GAIN